vaccine makers are counting on some of the unique features of the lungs, nose and throat, which are lined with mucosa. This tissue contains high levels of immune proteins, called IgA, that give better protection against respiratory viruses.Activating these immune weapons, they theorize, can protect areas deeper in the lungs where the SARS-CoV-2 does the most damage.
They also may improve vaccines’ chances of blocking transmission.“The first generation of vaccines are probably going to protect a lot of people," said Michael Diamond, an infectious disease specialist at Washington University in St.